Trial Profile
A Multicenter, Randomized, Controlled Trial of Combination Therapy for Lamivudine-Resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Clevudine (Primary) ; Adefovir; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- 22 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Feb 2009 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.
- 03 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.